The cuproptosis score helps evaluate cuproptosis patterns, prognosis, and TME cell infiltration, guiding treatment decisions. It predicts responses to hormone therapy, chemotherapy, and anti-PD-L1/PD1 immunotherapy. Targeting CRGs or cuproptosis-related genes could modify TME characteristics, enhancing immunotherapy efficacy and enabling personalized BRCA treatments. Here, CD274 is linked to invasive breast carcinoma.